Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

By John B. Buse, J. Rosenstock, G. Sesti, W. Schmidt, E. Montanya, J. Brett, M. Zychma, L. Blonde. The Lancet, 2009

1,530 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, methodology): “All data are from clinical trials reporting head-to-head comp vs liraglutide [37], lixisenatide vs liraglutide [38], exenatide once-weekly vs liraglutide [39], vs dulaglutide [42], and oral semaglutide vs liraglutide [43]) on a background of oral glucos equations to calculate common means and their ”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, neutral): “75 Exenatide .”
Type 1 diabetes: etiology, immunology, and therapeutic strategies. (2011, background): “Examples are Exenatide (Byetta by Amylin Pharmaceuticals and Eli Lilly), a synthetic version of the exendin-4 hormone found in the saliva of the Gila monster, and Liraglutide (Victoza by NovoNordisk), a GLP-1 analog that binds to albumin for slow release (76, 104).”